How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy

Barbara Jennings, Gavin Willis

Research output: Contribution to journalSpecial issue

21 Citations (Scopus)

Abstract

Folate was identified as an essential micronutrient early in the twentieth century and anti-folate chemotherapy such as 5-fluorouracil (5-FU) has been central to the medical management of solid tumours including colorectal cancer for more than five decades. In the intervening years, evidence has been gathered which shows that folate deficiency leads to many human diseases throughout the life-course. However, we still do not know all of the mechanisms behind functional folate deficiency, or indeed its rescue through supplementation with natural and particularly synthetic folates. There is growing evidence that one adverse effect of folic acid fortification programmes is an increased risk of colorectal cancer within populations. The complexity of folate-dependent, one-carbon metabolism and the heterogeneity that exists between individuals with respect to the enzymes involved in the anabolic pathways, and the catabolism of 5-FU, are explored in this review. The enzyme products of some genes such as MTHFR exert multiple and perhaps unrelated effects on many phenotypes, including cancer development. We describe this pleiotropy and the common genetic variants that affect folate metabolism; and discuss some of the studies that have investigated their potential as predictive biomarkers.
Original languageEnglish
Pages (from-to)224-230
Number of pages7
JournalCancer Letters
Volume356
Issue number2 Part A
Early online date12 Mar 2014
DOIs
Publication statusPublished - 28 Jan 2015

Keywords

  • Colorectal cancer
  • pharmacogenetics
  • Folate metabolism

Cite this